World of DTC Marketing

JUNE 15, 2025

Direct-to-consumer (DTC) pharmaceutical advertising is often caught in the crossfire of political debates. Senator Bernie Sanders, among other critics, has repeatedly asserted that DTC ads inflate healthcare costs by driving unnecessary prescriptions. But is this perspective supported by evidence? The reality tells a different story. DTC Ads Empower Patients Through Education Contrary to popular critiques, DTC advertisements serve as a crucial educational tool, enabling patients to engage more p

Doctor 195

Doctor Doctors Marketing Drugs 195

Scienmag

JUNE 15, 2025

A groundbreaking study from Amsterdam University Medical Center (Amsterdam UMC) has provided compelling evidence that video consultations between surgeons and patients are just as effective as traditional in-person visits when preparing for major abdominal surgery. Published in The Lancet Digital Health, this multicenter, randomized controlled trial demonstrates that virtual consultations do not compromise information transfer, patient satisfaction, or clinical communication quality.

Trials 75

Trials Clinical Research Research 75

NPR Health - Shots

JUNE 15, 2025

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with pitfalls. Here's his tips for how to use them successfully.

Doctors 110

Doctors Doctor Drugs 110

The Pharma Data

JUNE 15, 2025

Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. today presented new and significant data demonstrating the superiority of Dupixent® (dupilumab) over Xolair® (omalizumab) in a first-of-its-kind, head-to-head, Phase 4 study in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and co-existing asth

Allergies 40

Allergies Clinical Trials Clinical Trials Trials 40

Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group

Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.

Compliance

Velocity Clinical Research

JUNE 15, 2025

At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to listen, learn, and lead—and it’s why we’re excited to share insights from our latest nationwide patient survey.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Clinical Research 59

The Pharma Data

JUNE 15, 2025

QIAGEN and Incyte Forge Global Collaboration to Develop Companion Diagnostic Panel for Patients With Mutant CALR-Positive Myeloproliferative Neoplasms QIAGEN N.V. and Incyte today announced a significant new collaboration aimed at improving the standard of care for patients battling myeloproliferative neoplasms (MPNs) — a group of rare but serious blood disorders — by developing a novel, multimodal diagnostic panel designed to aid clinician decision-making and enable the delivery of more persona

Genomics 40

Genomics Genome Gene Development 40

The Pharma Data

JUNE 15, 2025

Genmab Presents Positive Epcoritamab Combination Data in Relapsed or Refractory DLBCL Eligible for Autologous Stem Cell Transplantation Genmab A/S today shared new and highly promising data from its Phase 1b/2 EPCORE® NHL-2 trial (Arm 10, NCT04663347) evaluating its T-cell-engaging bispecific antibody, epcoritamab, in combination with rituximab, ifosfamide, carboplatin, and etoposide — a regimen collectively known as R-ICE — in adult patients with relapsed or refractory (R/R) diffuse large B-cel

Antibody 40

Antibody Trials Containment Clinical Trials 40

Pharma Marketing Network

JUNE 15, 2025

Managing large email lists in the pharmaceutical industry is no small feat. So, how do leading brands make their pharma email marketing campaigns not only compliant—but effective—at scale? Imagine managing a stadium-sized audience where each person expects personalized, relevant communication—and regulators are watching every move. That’s what email marketing looks like in pharma.

Marketing 52

Marketing Compliance Branding Regulation 52

The Pharma Data

JUNE 15, 2025

Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update for ELEVIDYS (delandistrogene moxeparvovec-rokl). ELEVIDYS is currently the only U.S. Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD).

Immune Response 40

Immune Response Gene Therapy Regulation Gene 40

Pharma Marketing Network

JUNE 15, 2025

What if one pill a day could protect you from HIV? Thanks to modern medicine, HIV prevention medications are not only real—they’re reshaping public health and empowering people to take control of their sexual wellness. Although HIV awareness has improved, misconceptions still cloud the public’s understanding of prevention strategies. Some people don’t know these options exist, while others misunderstand how they work or who they’re for.

FDA Approval 52

FDA Approval Drugs Doctor Doctors 52

Advertisement

Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness

Trials

The Pharma Data

JUNE 15, 2025

Johnson & Johnson’s RedirecTT-1 Study Shows Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease Johnson & Johnson today presented new and promising data from its Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) — two first-in-class, FDA-approved bispecific antibodies — in patients battling triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM) wi

Antibody 40

Antibody FDA Approval Compliance Medicine 40

JAMA Internal Medicine

JUNE 15, 2025

This cross-sectional study measures associations between the first end-of-year American Board of Internal Medicine Longitudinal Knowledge Assessment progress report scores and patient outcomes among hospitalists.

Medicine 40

Medicine 40

The Pharma Data

JUNE 15, 2025

Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated and extensive follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study evaluating lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002) in patients with hereditary angioedema (HAE).

Genomics 40

Genomics Genome Allergies Medicine 40

BioTech 365

JUNE 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial … Continue reading →

Allergies 52

Allergies Trials 52

Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk

In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?

Compliance

The Pharma Data

JUNE 15, 2025

Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of its benefit-risk profile in non-ambulatory patients with Duchenne muscular dystrophy (DMD). This update comes after two cases of fatal acute liver failure (ALF) were reported in non-ambulatory DMD patients who received Elevidys, a phenomenon that underscores the ongo

Regulation 40

Regulation Trials Clinical Trials Clinical Trials 40

JAMA Internal Medicine

JUNE 15, 2025

This cohort study compares the risks of adverse liver outcomes, major adverse cardiovascular events, and all-cause mortality across steatotic liver disease subtypes.

50

50

STAT News

JUNE 15, 2025

Sarepta Therapeutics said Sunday that it was halting shipments of its Duchenne muscular dystrophy gene therapy for patients who can no longer walk, following the death of a second person who received the treatment. Sarepta disclosed the first patient death — a 16-year-old boy — in March. Both occurred from acute liver failure, a side effect that has been seen with other gene therapies.

Gene Therapy 144

Gene Therapy Gene Drugs Genetics 144

BioTech 365

JUNE 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable … Continue reading →

Antibody 52

Antibody 52

Advertisement

Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.

Life Science

Scienmag

JUNE 15, 2025

A groundbreaking new study reveals that violence and fear of violence in the workplace are far more pervasive and damaging than previously understood, painting a sobering picture of the modern labor environment. According to the research, co-authored by experts Dr Vanessa Gash from City, St George’s, University of London and Dr Niels Blom from the University of Manchester, one in twelve workers across various industries in the United Kingdom has faced threats, insults, or physical attacks at wor

Research 64

Research Production Marketing 64

BioTech 365

JUNE 15, 2025

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) QIAGEN to … Continue reading →

Medicine 52

Medicine Development 52

Scienmag

JUNE 15, 2025

A groundbreaking study from researchers B. Karaş and A. Shokrani has introduced an innovative approach to understanding the costs associated with laser powder-bed additive manufacturing (LPBFAM), a leading-edge technology revolutionizing the production landscape. Published in the esteemed journal npj Advanced Manufacturing, this research combines the financial rigor of activity-based costing (ABC) with the dynamic insights of discrete event simulation (DES) to deliver an unprecedented analytical

Manufacturing 59

Manufacturing Production Engineer Research 59

BioTech 365

JUNE 15, 2025

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of … Continue reading →

Development 40

Development 40

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Pharma Marketing Network

JUNE 15, 2025

In an industry where trends shift rapidly and regulations tighten often, having access to expert insight and reliable peer connections is vital. That’s where the Pharma Marketing Network comes in. For over two decades, the Pharma Marketing Network has served as a central hub for pharmaceutical, biotech, and life sciences professionals focused on marketing, branding, and digital innovation.

Marketing 52

Marketing Branding Regulation Compliance 52

BioTech 365

JUNE 15, 2025

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in … Continue reading →

52

52

NPR Health - Shots

JUNE 15, 2025

On Father's Day, Esther Ngumbi thinks of the sacrifices her Kenyan dad made to ensure that not only his son but his four daughters got an education. He'd say, "I choose to educate you, my girls.

84

84

BioTech 365

JUNE 15, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor – Pharmacology modeling data … Continue reading →

Antibody 52

Antibody 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

JAMA Internal Medicine

JUNE 15, 2025

This essay describes the author’s lived experience with balancing religious practices with practicing medicine.

Medicine 40

Medicine 40

BioTech 365

JUNE 15, 2025

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne – The Company is developing an … Continue reading →

Development 52

Development 52

NPR Health - Shots

JUNE 15, 2025

Health Secretary Robert F. Kennedy Jr. fired all the people serving on a national vaccine advisory board. NPR's Ayesha Rascoe speaks to Edwin Asturias, one of the doctors who was sacked.

Doctors 53

Doctors Doctor Vaccine Vaccination 53

BioTech 365

JUNE 15, 2025

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease Data from Phase IIb PADOVA study and longer term follow-up data suggest … Continue reading →

Development 40

Development 40

Advertisement

Clinical Supply